B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: Predictive value and response to disease targeting therapy

Heart

Volumn 98, Issue 9, 2012, Pages 736-742

  Diller, Gerhard Paul ^a,b   Alonso Gonzalez, Rafael ^a   Kempny, Aleksander ^a   Dimopoulos, Konstantinos ^a,b   Inuzuka, Ryo ^a   Giannakoulas, Georgios ^a   Castle, Lianne ^a   Lammers, Astrid E ^a   Hooper, James ^a   Uebing, Anselm ^a   Swan, Lorna ^a   Gatzoulis, Michael ^a,b   Wort, Stephen J ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; SILDENAFIL;

ADULT; ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; DRUG EFFICACY; DRUG TARGETING; EISENMENGER COMPLEX; EXERCISE TEST; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; TERTIARY HEALTH CARE; TREATMENT RESPONSE;

ADULT; BIOLOGICAL MARKERS; CARDIAC SURGICAL PROCEDURES; CAUSE OF DEATH; EISENMENGER COMPLEX; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS;

EID: 84860127306     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301522     Document Type: Article

References (31)

1. Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011;58:538-46.
2. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007;115:1039-50. (Pubitemid 46328298)
3. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006;27:1737-42. (Pubitemid 44025362)
4. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121:20-5.
5. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54. (Pubitemid 44305274)
6. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
7. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
8. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8. (Pubitemid 28064743)
9. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-5.
10. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
11. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. (Pubitemid 34764819)
12. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
13. Gabriel RS, Kerr AJ, Sharma V, et al. B-type natriuretic peptide and left ventricular dysfunction on exercise echocardiography in patients with chronic aortic regurgitation. Heart 2008;94:897-902. (Pubitemid 351914702)
14. Ishwaran H, Kogalur UB, Blackstone EH, et al. Random survival forests. Ann Appl Stat 2008;3:841-60.
15. Ishwaran H, Kogalur UB, Gorodeski EZ, et al. High-dimensional variable selection for survival data. J Am Stat Assoc 2010;105:205-17.
16. Hsich E, Gorodeski EZ, Blackstone EH, et al. Identifying important risk factors for survival in patient with systolic heart failure using random survival forests. Circ Cardiovasc Qual Outcomes 2011;4:39-45.
17. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44. (Pubitemid 30422619)
18. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13. (Pubitemid 28020159)
19. Somerville J. How to manage the Eisenmenger syndrome. Int J Cardiol 1998;63:1-8. (Pubitemid 28060219)
20. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-71. (Pubitemid 41785867)
21. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63. (Pubitemid 38364624)
22. Davlouros PA, Niwa K, Webb G, et al. The right ventricle in congenital heart disease. Heart 2006;92(Suppl 1):i27-38.
23. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006;114:1883-91. (Pubitemid 44673364)
24. Porapakkham P, Zimmet H, Billah B, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010;170:507-14.
25. Squire I, Quinn P, Narayan H, et al. Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP. Heart 2010;96:831-7.
26. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63. (Pubitemid 41632043)
27. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-95.
28. Sitbon O, Galie N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev 2010;19:272-8.
29. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005;112:828-35. (Pubitemid 41170068)
30. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124-31.
31. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012;155:378-82.